Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZW251 in Advanced Solid Tumors
NCT07164313Phase 1Recruiting
- Sponsor
- Zymeworks Inc.
- Start
- Oct 2025
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of ZW251 in hepatocellular carcinoma (HCC), squamous cell carcinoma of the lung (SCCL) and germ cell tumor (GCT), sponsored by Zymeworks Inc. Primary endpoints: Incidence of dose-limiting toxicities at 3 weeks, Incidence of Adverse Events at 2 years and 2 more. Started Oct 2025; status: recruiting.
02
Drugs
ZW251
03
Conditions
hepatocellular carcinoma (HCC)squamous cell carcinoma of the lung (SCCL)germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT07164313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07164313.